Seguro Popular To Include Hemophilia Treatment For Children
BMI View: It is encouraging for multinational pharmaceutical companies that Mexico plans to include more high-cost treatments within Seguro Popular. However, low healthcare spending in Mexico is a fundamental factor that hinders the access of innovative medicines in the country. Nevertheless, the regular access to healthcare through social protection schemes can reduce out-of-pocket payments on basic healthcare services and free up resources for more advanced medical treatments.
Mexico's national health insurance programme, Seguro Popular, has included the treatment of haemophilia for children, which can cost up to MXN60,000 (USD4,620) per unit. We note that the programme includes all treatments for children, and it is reportedly to invest around MXN7mn (USD54,000) per year for children's healthcare. However, the local health authority estimated that the programme needs extra investment of MXN4mn (USD310,000) per year in order to include high-cost treatment for haemophilia such as anti-haemophilic factor.
Launched in 2003, Seguro Popular was designed to tackle widespread inefficiencies and inconsistencies in the country's healthcare system, and aims to provide health insurance coverage for those in Mexico that were not already covered by another programme. Over the past decade, Seguro Popular has improved access to healthcare services and reduced the prevalence of catastrophic healthcare costs, especially for those on low incomes The scheme guarantees access to over 250 medical interventions, including all services provided in ambulatory clinics and general hospitals. It also covers a package of 18 expensive interventions, including all treatment for children, HIV/AIDS, and cervical and breast cancer. Seguro Popular's current budget for each patient is only around USD200 per year.
|Personal Healthcare Expenditure Drops|
|Mexican Household Expenditure Between 2008 And 2010 (In MXN)|